Paper · 22871663
References35
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
1 to 20 of 35
Download this page as JSON| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 20,587,792 | Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. | J Natl Cancer Inst | 2010 | https://conductscience.org/library/papers/20587792 | PubMed |
| 2 | 18,401,435 | Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma. | Gene Ther | 2008 | https://conductscience.org/library/papers/18401435 | PubMed |
| 3 | 18,981,012 | A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. | Clin Cancer Res | 2008 | https://conductscience.org/library/papers/18981012 | PubMed |
| 4 | 19,572,105 | Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors. | Invest New Drugs | 2010 | https://conductscience.org/library/papers/19572105 | PubMed |
| 5 | 11,007,773 | Transcriptional activities of reovirus RNA polymerase in recoated cores. Initiation and elongation are regulated by separate mechanisms. | J Biol Chem | 2000 | https://conductscience.org/library/papers/11007773 | PubMed |
| 6 | 9,628,872 | The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. | EMBO J | 1998 | https://conductscience.org/library/papers/9628872 | PubMed |
| 7 | 2,982,027 | Reovirus serotype 1 intestinal infection: a novel replicative cycle with ileal disease. | J Virol | 1985 | https://conductscience.org/library/papers/2982027 | PubMed |
| 8 | 4,371,523 | The reovirus murine models. | Prog Med Virol | 1974 | https://conductscience.org/library/papers/4371523 | PubMed |
| 9 | 19,773,377 | Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. | Clin Cancer Res | 2009 | https://conductscience.org/library/papers/19773377 | PubMed |
| 10 | 19,594,950 | Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells. | Mol Cancer | 2009 | https://conductscience.org/library/papers/19594950 | PubMed |
| 11 | 19,884,534 | Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. | J Clin Oncol | 2009 | https://conductscience.org/library/papers/19884534 | PubMed |
| 12 | 18,172,278 | Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. | Clin Cancer Res | 2008 | https://conductscience.org/library/papers/18172278 | PubMed |
| 13 | 21,886,163 | Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. | Nature | 2011 | https://conductscience.org/library/papers/21886163 | PubMed |
| 14 | 21,107,323 | Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. | Nature | 2010 | https://conductscience.org/library/papers/21107323 | PubMed |
| 15 | 20,801,221 | The use of immunohistochemistry to determine oncolytic reovirus distribution and replication in-human tumors. | Methods | 2010 | https://conductscience.org/library/papers/20801221 | PubMed |
| 16 | 21,106,728 | A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. | Clin Cancer Res | 2011 | https://conductscience.org/library/papers/21106728 | PubMed |
| 17 | 19,509,134 | Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. | Clin Cancer Res | 2009 | https://conductscience.org/library/papers/19509134 | PubMed |
| 18 | 11,932,414 | Reovirus core protein mu2 determines the filamentous morphology of viral inclusion bodies by interacting with and stabilizing microtubules. | J Virol | 2002 | https://conductscience.org/library/papers/11932414 | PubMed |
| 19 | 21,639,808 | Improved survival with vemurafenib in melanoma with BRAF V600E mutation. | N Engl J Med | 2011 | https://conductscience.org/library/papers/21639808 | PubMed |
| 20 | 20,528,232 | OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. | Future Oncol | 2010 | https://conductscience.org/library/papers/20528232 | PubMed |
papers-2026-11-12-0.1.0
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/papers/v1/22871663/references